CollPlant Biotechnologies Ltd. (CLGN) |
|
12.99 1.78 (15.88%)
|
01-27 15:59 |
|
Open: |
11.21 |
Pre. Close: |
11.21 |
|
High:
|
13.02 |
Low:
|
10.97 |
|
Volume:
|
58,569 |
Market Cap:
|
145(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:24 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 15.2  One year: 17.76 |
| Support: |
Support1: 9.71 Support2: 7.67 |
| Resistance: |
Resistance1: 13.02 Resistance2: 15.2 |
| Pivot: |
9.44 |
| Moving Average: |
MA(5): 10.81 MA(20): 9.25
MA(100): 7.43 MA(250): 8.56 |
| MACD: |
MACD(12,26): 0.8 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 90.5 %D(3): 83.6 |
| RSI: |
RSI(14): 78.6 |
| 52-week: |
High: 14.77 Low: 4.26 |
| Average Vol(K): |
3-Month: 32 (K) 10-Days: 24 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLGN ] has closed It is unclear right now based on current values. 137.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
13.04 - 13.1 |
13.1 - 13.16 |
|
Low:
|
10.84 - 10.9 |
10.9 - 10.96 |
|
Close:
|
12.87 - 12.99 |
12.99 - 13.1 |
|
Company Description |
|
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel. |
Headline News |
Sat, 28 Jan 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest ... - MarketBeat
Fri, 27 Jan 2023
Top 5 Health Care Stocks That May Dip - Benzinga
Tue, 24 Jan 2023
CollPlant Issues Letter to Shareholders - January 24, 2023 - BioSpace
Tue, 17 Jan 2023
Should You Sell Collplant Biotechnologies Ltd - ADR (CLGN) in Biotechnology Industry? - InvestorsObserver
Thu, 05 Jan 2023
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) market cap rose US$13m last week; individual investors who hold 50% profited and so did insiders - Simply Wall St
Wed, 04 Jan 2023
Collplant Biotechnologies Ltd - ADR (CLGN) is higher by 10.25% in a Week, Should You Sell? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
7.75e+006 (%) |
|
% Held by Institutions
|
10.1 (%) |
|
Shares Short
|
27 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.481e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
870.2 |
|
Return on Equity (ttm)
|
-21 |
|
Qtrly Rev. Growth
|
551000 |
|
Gross Profit (p.s.)
|
-32.03 |
|
Sales Per Share
|
-56.05 |
|
EBITDA (p.s.)
|
1.97681e+007 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-13 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.24 |
|
Price to Cash Flow
|
2.77 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
24610 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2016-11-20 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
